A federal appeals court panel hears arguments over whether prescribing rules should be tightened for mifepristone, a drug used in medication abortions, which are among the most common abortion methods in the United States. The case focuses on whether federal restrictions related to the drug’s use should be narrowed or expanded through updated regulatory requirements.
The hearing takes place in the broader context of abortion policy changes following the U.S. Supreme Court’s decision in 2022 that allows states to set their own abortion rules. Multiple lawsuits and regulatory efforts are currently underway nationwide, reflecting ongoing disagreements over access to medication abortion. Both outlets describe the same core procedural moment—judges considering a push to restrict mifepristone—though they characterize it as part of continuing efforts to limit abortion access.
While the reporting emphasizes the legal review of prescribing rules, it does not identify the outcome of the panel’s deliberations or provide details in the excerpts about the specific changes sought beyond tightening mifepristone-related requirements.
